Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SLDB
SellHot AirSolid Biosciences Inc. · Healthcare · United States · $1.0B · Avg Vol: $8M/d
COMPANY DESCRIPTION
Solid Biosciences Inc. is a clinical-stage gene therapy company dedicated to developing transformative treatments for Duchenne muscular dystrophy (DMD). The company's competitive edge lies in its proprietary AAV-based gene therapy platform designed to deliver functional dystrophin to muscle cells, addressing the underlying cause of the disease. It operates as a highly specialized biotech player focused on a single, severe rare genetic disorder with significant unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.6M | 8.1M | 0 | 0 | 0 | -40.6% | — | — | 10.0M | 4.2% |
| EPS | -10.14 | -2.01 | -1.00 | -1.26 | -1.99 | — | -1.89 | -1.76 | -1.75 | — |
| Shares | 7.4M | 98.4M | 98.4M | 98.4M | 79.0M | +973.5% | — | — | — | — |
| Debt | 2.1M | 28.5M | 26.3M | 24.2M | 21.2M | 79.0% | 20.2M | — | — | — |
| Equity | 208.2M | 211.7M | 126.5M | 137.2M | 180.0M | -3.6% | — | — | — | — |
| Op CF | -77.8M | -98.0M | -94.2M | -100.0M | -156.3M | — | -186.8M | — | — | — |
| Inv CF | -91.1M | 59.2M | 9.7M | -16.1M | -58.5M | — | — | — | — | — |
| Fin CF | 135.0M | 74.8M | 3.1M | 122.4M | 194.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLDB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SLDB | Solid Biosciences Inc.(you) | $1.0B | 33 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 28 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 29 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| FTH | Faeth Therapeutics, Inc. | $874M | 30 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 28 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 27 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 26 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%